Dark

Check out our Level2View

LABP
Landos Biopharma, Inc. Common Stock
stock NASDAQ

Inactive

May 23, 2024

22.93USD+0.583%(+0.13)50,899

Pre-market

Dec 31, 1969 7:00:00 PM EST

0.00USD-100.000%(-22.80)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 3, 2022

12:23PM EST What 4 Analyst Ratings Have To Say About Landos Biopharma Benzinga

11:19AM EST JP Morgan Maintains Neutral on Landos Biopharma, Lowers Price Target to $7 Benzinga

Nov 16, 2021

10:11AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2021 Benzinga

07:20AM EST SVB Leerink Downgrades Landos Biopharma to Market Perform, Lowers Price Target to $16 Benzinga

Nov 15, 2021

10:59AM EST Landos Biopharma Q3 EPS $(0.32) Benzinga

07:30AM EST Enhancing Focus on High-Impact Clinical-Stage Programs to Ensure Optimal Path to Commercialization GlobeNewswire Inc

Nov 11, 2021

04:05PM EST Landos Biopharma Inc. (NASDAQ: LABP) today announced that it will report third quarter 2021 financial results and host a conference call to provide a corporate update on November 15, 2021. GlobeNewswire Inc

Nov 8, 2021

08:29AM EST Landos Biopharma Announces Josep Bassaganya-Riera Will Step Down As Chairman, President And CEO; Tim M. Mayleben Appointed Interim President And CEO Benzinga

08:10AM EST Josep Bassaganya-Riera Steps Down as Chairman, President and CEO GlobeNewswire Inc

Nov 2, 2021

10:57AM EDT Landos Biopharma Announces FDA Clearance Of IND For LABP-104 For Treatment Of Rheumatoid Arthritis Benzinga

08:28AM EDT Phase 1 trial is underway with topline results expected in the first half of 2022 GlobeNewswire Inc

Oct 28, 2021

07:35AM EDT Landos Biopharma Announces First Subject Dosed In A Phase 1 Study Of LABP-104 For Systemic Lupus Erythematosus Benzinga

07:00AM EDT Landos Biopharma Announces First Subject Dosed in a Phase 1 Study GlobeNewswire Inc

Oct 20, 2021

10:14AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2021 Benzinga

08:24AM EDT Craig-Hallum Initiates Coverage On Landos Biopharma with Buy Rating, Announces Price Target of $45 Benzinga

Oct 19, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021 Benzinga

06:20AM EDT HC Wainwright & Co. Initiates Coverage On Landos Biopharma with Buy Rating, Announces Price Target of $50 Benzinga

Oct 11, 2021

07:19AM EDT Landos Biopharma: FDA Clears IND Application For LABP-104 For Systemic Lupus Erythematosus RTTNews

07:02AM EDT Landos Biopharma Announces FDA Clearance Of Its IND For LABP-104 For The Treatment Of Systemic Lupus Erythematosus Benzinga

07:00AM EDT Phase 1 trial initiation expected before yearend with topline results in 1H 2022 GlobeNewswire Inc

Oct 6, 2021

07:06AM EDT Landos Biopharma Announces Publication In Scientific Reports Of Novel Preclinical Findings Demonstrating Omilancor's Therapeutic Potential In Models Of Psoriasis And Further Validating The LANCL2 Mechanism Benzinga

07:00AM EDT Landos Biopharma Announces Publication in Scientific Reports of GlobeNewswire Inc

Sep 27, 2021

07:00AM EDT Landos Biopharma to Participate in Truist Securities CEO Fireside GlobeNewswire Inc

Sep 23, 2021

10:06AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021 Benzinga

07:36AM EDT JonesTrading Initiates Coverage On Landos Biopharma with Buy Rating, Announces Price Target of $39 Benzinga

Sep 20, 2021

07:16AM EDT Landos Biopharma To Collaborate On A Phase 2 Study Of Omilancor In Crohn's Disease With The Icahn School Of Medicine At Mount Sinai Benzinga

07:00AM EDT Second Phase 2 trial of omilancor in Crohns disease (CD), expected to initiate in 2021 GlobeNewswire Inc

Sep 15, 2021

07:00AM EDT Oral treatment with LABP-104 in preclinical models of Systemic Lupus Erythematosus (SLE) resulted in enhanced Treg function, decreased kidney inflammation and reduced interferon gamma signaling GlobeNewswire Inc

Sep 1, 2021

07:00AM EDT Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos will participate in two upcoming virtual investor conferences in September. GlobeNewswire Inc

Aug 26, 2021

07:00AM EDT Landos Biopharma Announces Research Collaboration into the NLRX1 GlobeNewswire Inc

Aug 5, 2021

07:00AM EDT Landos Biopharma to Participate in Upcoming Investor Events GlobeNewswire Inc

Jul 30, 2021

08:33AM EDT Raymond James Maintains Outperform on Landos Biopharma, Raises Price Target to $35 Benzinga

Jul 29, 2021

07:30AM EDT Following the recent positive End-of-Phase 2 meeting with the FDA, Landos initiated global pivotalPhase 3 clinical trial site feasibility studies of omilancor in ulcerative colitis (UC) GlobeNewswire Inc

Jul 22, 2021

07:14AM EDT Landos Biopharma's Phase 2 Data of Omilancor in Ulcerative Colitis Accepted for Oral Presentation at the United European Gastroenterology Week 2021 Benzinga

07:00AM EDT Omilancor shows efficacy and tolerability as a potential once-daily, oral, gut-restricted therapy for mild-to-moderate UC patients GlobeNewswire Inc

Jun 14, 2021

05:08PM EDT Landos Biopharma to Present at the Raymond James Virtual Human GlobeNewswire Inc

07:06AM EDT Landos Biopharma Announces Outcome Of End-Of-Phase 2 Meeting With FDA For Omilancor In Mild-To-Moderate Active Ulcerative Colitis; Co. And FDA Agreed On Key Elements Necessary For Approval Benzinga

07:00AM EDT Landos Biopharma Announces Positive Outcome of End-of-Phase 2 GlobeNewswire Inc

May 25, 2021

07:00AM EDT Landos Biopharma to Present at the Jefferies Virtual Healthcare GlobeNewswire Inc

May 19, 2021

07:00AM EDT Landos Biopharma Announces the Appointment of Tim M. Mayleben to GlobeNewswire Inc

May 17, 2021

10:22AM EDT Landos Biopharma shares were trading higher after the company reported Q1 EPS results up from last year. Benzinga

09:30AM EDT Landos Biopharma, LianBio Ink Licensing Pact For Omilancor & NX-13 in Greater China Benzinga

07:20AM EDT Landos Biopharma and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Omilancor and NX-13 in Greater China and Select Asian Markets Benzinga

07:20AM EDT Landos Biopharma Q1 EPS $(0.38) Up From $(0.49) YoY Benzinga

07:15AM EDT Completed initial public offering of common stock, raising approximately $100 million in gross proceeds GlobeNewswire Inc

07:12AM EDT Landos Biopharma, LianBio Announce License Deal To Develop Omilancor And NX-13 In Greater China And Select Asian Markets RTTNews

07:00AM EDT Landos Biopharma and LianBio Announce Exclusive Collaboration and GlobeNewswire Inc

May 6, 2021

04:30PM EDT Landos Biopharma Announces First Patient Dosed In Phase 2 Study Of Omilancor For Moderate-To-Severe Crohn's Disease Benzinga

Apr 29, 2021

07:26AM EDT Landos Biopharma Announces First Patient Dosed In A Phase 1b Study of NX-13 For Ulcerative Colitis Benzinga

07:00AM EDT Landos second first-in-class product candidate designed to provide a safer and more convenient treatment for ulcerative colitis patients GlobeNewswire Inc

Apr 26, 2021

07:00AM EDT -- Robust preclinical data supports breadth and growth of Landos autoimmune-focused pipeline -- Company expects to submit an IND for omilancor as a topical treatment for psoriasis in 2H 2021 -- Company expects to submit an IND for PX-69 as an oral treatment for rheumatoid arthritis in 1H 2022 GlobeNewswire Inc

Apr 13, 2021

07:17AM EDT Landos Biopharma Names Tiago Giro To Board RTTNews

07:00AM EDT Landos Biopharma Announces the Appointment of Tiago GlobeNewswire Inc

Apr 6, 2021

09:53AM EDT Landos Biopharma Stock Is Trading Higher On Initiating Early-Stage Study With Omilancor For Esophagus Inflammation Benzinga

08:05AM EDT The Daily Biotech Pulse: Illumina Lights Up, Cara Soars On Index Inclusion, Novavax Starts Crossover Vaccine Study, Turning Point Data Readout Benzinga

07:20AM EDT Landos Reports FDA Clearance Of IND Application For Omilancor For Eosinophilic Esophagitis RTTNews

07:02AM EDT Landos Biopharma Announces FDA Clearance of IND Application for Omilancor for the Treatment of Eosinophilic Esophagitis Benzinga

07:00AM EDT Landos Biopharma Announces FDA Clearance of IND Application for GlobeNewswire Inc

Mar 31, 2021

07:41AM EDT The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO Benzinga

Mar 30, 2021

08:06AM EDT The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings Benzinga

Mar 4, 2021

07:22AM EST Landos Biopharma Announces Positive Results from a Phase 1 Study of NX-13 in Healthy Volunteers; Landos Reports 'All primary and secondary endpoints in the Phase 1 study of NX-13 were met' Benzinga

07:00AM EST Landos Biopharma Announces Positive Results from a Phase 1 Study GlobeNewswire Inc

Mar 3, 2021

07:46AM EST The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine Study Benzinga

Mar 2, 2021

08:01AM EST The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data Benzinga

Mar 1, 2021

11:17AM EST Jefferies Initiates Coverage On Landos Biopharma with Buy Rating, Announces Price Target of $32 Benzinga

11:10AM EST JP Morgan Initiates Coverage On Landos Biopharma with Neutral Rating, Announces Price Target of $17 Benzinga

10:14AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2021 Benzinga

07:10AM EST Raymond James Maintains Outperform on Landos Biopharma, Announces $33 Price Target Benzinga

07:00AM EST SVB Leerink Initiates Coverage On Landos Biopharma with Outperform Rating, Announces Price Target of $20 Benzinga

Feb 27, 2021

09:04PM EST The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings Benzinga

Feb 23, 2021

04:00PM EST Landos Biopharma to Participate in the SVB Leerink 10th Annual GlobeNewswire Inc

Feb 19, 2021

07:25AM EST The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko Benzinga

Feb 13, 2021

12:54PM EST The Past Week's Notable Insider Buys: Biotech IPOs, Curiositystream, Greenbrier And More Benzinga

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

Feb 5, 2021

07:44AM EST The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street Benzinga

Feb 4, 2021

12:11PM EST Landos Biopharma Shares Open At $13; IPO Priced At $16/Share Benzinga

10:44AM EST Landos Bipharma Shares Indicating $14.56 Benzinga

Feb 3, 2021

10:06PM EST Landos Biopharma Prices IPO Of 6.25 Mln Shares At $16.00/shr RTTNews

08:14PM EST Landos Biopharma Announces Pricing of Initial Public Offering GlobeNewswire Inc

Share